The MIT-associated mutations (KRAS, TP53, PDZRN3, ADAMTSL4 and CDKN2A) were commonly observed in the samples from a pan-cancer dataset with ICB clinical information and mutation data, and various cancer types including NSCLC, BLCA, SKCM, and EC with the frequencies greater than 10% (Figure 5C). Here, PDZRN3 is linked to bladder transitional cell carcinoma.